RARE News - Candlesense

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

NOVATO, Calif., Aug. 21, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies fo...

Compensation

1 day ago

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc. - RARE

NEW YORK, Aug. 11, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Ultragenyx Pharmaceutical Inc. ("Ultragenyx" or the "Company") (NASDAQ: RARE). Such investors...

How should the current position be adjusted to manage risk and potential upside given the uncertainty surrounding the lawsuit? What is the likelihood of a material adverse change (MAC) event that could trigger a breach of existing debt covenants? Might the lawsuit affect existing financing arrangements, credit facilities, or covenant compliance for the company?

Lawsuits

12 days ago